Introduction
The EFFIMABTM precision monoclonal antibody discovery platform is a monoclonal antibody development technology innovated based on more than 20 years of experience in antibody development. The platform combines the advantages of the stable and reliable hybridoma technology and high efficiency of the single-B cell technology, which can well meet the needs of diagnostic and therapeutic antibody development. On the EFFIMABTM platform, we provide our customers with high quality monoclonal antibody discovery services.
Using the EFFIMABTM platform, the time cost of obtaining binding antibodies is shortened by more than 50% compared with traditional hybridoma technology, the antibody acquisition efficiency is increased by more than 10 times . Moreover it can meet the technical requirements for rare antibody discovery such as high-affinity antibodies and antibodies with special function.
Produce
Items | Time（week） | Results |
Antigen Preparation | By case | Antigen preparation methods include: peptide synthesis and coupling, protein expression, DNA, etc. |
Mouse Immunization | 8 | 3-5 mice, standard immunization program or individualized immunization program |
Hybridoma Construction | 8 | 5 antigen-binding monoclonal antibody cell culture supernatants, 1 hybridoma cell line (and variable region gene sequence) |
8 | 50 antigen-binding monoclonal antibody cell culture supernatants, 10 hybridoma cell lines (and variable region gene sequence) | |
8 | 100 antigen-binding monoclonal antibody cell culture supernatants, 20 hybridoma cell lines (and variable region gene sequence) | |
Specific Screening | / | Meet certain requirements, such as: recognition/non-recognition of a certain epitope or modification |
Affinity Determination | 1 | Determination of antibody affinity constants |
Variable region gene acquisition | 1 | Obtain the heavy and light chain variable region genes and sequences of the antibody |
Antibody Production | 4 | Antibody purity>90% |
Note: Each service item can be independent and superimposed
Antibody function is the core to realize its diagnostic and therapeutic value. HKIG has created functional monoclonal antibody development services by using technologies such as immunology, cell biology, and molecular biology. These personalized services help customers obtain monoclonal antibodies with extraordinary biological functions.
Items | Content | Results |
Neutralization | Use immunology and cell biology techniques to screen and obtain monoclonal antibodies that can block the binding of antigens and their ligands | 1-3 high-affinity monoclonal antibodies with the function of blocking the binding of antigen and its ligand |
Activation/Inhibition Signaling Pathway | Personalized design scheme, comprehensive use of immunology and cell biology techniques to screen out monoclonal antibodies with the ability to activate or inhibit a certain signaling pathway | 1-3 high-affinity monoclonal antibodies that activate or inhibit a certain signaling pathway |
Anti-idiotypic | Use special strategies to screen and obtain anti-idiotypic monoclonal antibodies to facilitate immunogenicity and pharmacokinetic studies of antibody drugs | 1 anti-idiotypic monoclonal antibody, 1 high-sensitivity ELISA immunoassay method based on anti-idiotypic monoclonal antibody |
Pairing | Different immunoassay methods are used to screen and obtain paired monoclonal antibodies that can detect the target antigen | 1 pair of monoclonal antibodies, 1 high-sensitivity “sandwich” ELISA immunoassay based on paired antibodies |
Typical Case
A cytokine is an important effector molecule of inflammatory response and a pathogenic factor of many autoimmune diseases. Using the EFFIMABTM precision monoclonal antibody development platform, HKIG has developed a series of high-affinity monoclonal antibodies that bind to the human and mouse cytokines for customers. On this basis, an individualized experimental plan was designed, and a variety of immunological techniques were used to screen and obtain several monoclonal antibodies with the function of blocking the combination of the cytokine and its specific receptor. In addition, HKIG has further screened and obtained a paired monoclonal antibody that recognizes the cytokine with high affinity, using which constructed a high-sensitivity ELISA immunoassay method. The above work has provided a solid foundation for the client to carry out the development of therapeutic drugs and diagnostic products targeting this cytokine.
ELISA to detect the blocking effect of the monoclonal antibodies targeting the cytokine.
Sandwich ELISA to detect the target cytokine. LoB<0.5ng/mL R2>0.99